ProCE Banner Activity

My Take on Frontline Chemoimmunotherapy for Extensive-Stage Small-Cell Lung Cancer

Clinical Thought
Read my thoughts on the importance of using combination chemoimmunotherapy as first-line treatment for extensive-stage SCLC.

Released: October 13, 2020

Expiration: October 12, 2021

No longer available for credit.

Share

Faculty

Taofeek K. Owonikoko

Taofeek K. Owonikoko, MD, PhD

Professor
Department of Hematology and Medical Oncology
Co-Leader, Thoracic Oncology
Emory University
Atlanta, Georgia

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Taofeek K. Owonikoko, MD, PhD

Professor
Department of Hematology and Medical Oncology
Co-Leader, Thoracic Oncology
Emory University
Atlanta, Georgia

Taofeek K. Owonikoko, MD, PhD, has disclosed that he has received funds for research support paid to his institution from AbbVie, Aeglea, Amgen, Astellas, AstraZeneca/MedImmune, Bayer, Bristol-Myers Squibb, Celgene, Corvus, Fujifilm, G1 Therapeutics, Incyte, Loxo/Lilly, Merck, Novartis, Pfizer, Regeneron, Stemcentrx, and United Therapeutics; has received consulting fees from AbbVie, Amgen, Armo, AstraZeneca, Bayer, BerGenBio, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, EMD Serono, G1 Therapeutics, Heron, Lilly, MedImmune, Merck, Novartis, PharmaMar, Sandoz, Seattle Genetics, Takeda, and Xcovery; has received fees for non-CME/CE services from EMD Serono and Roche/Genentech; and has ownership interests in Cambium.